Top Markets
#1 ADO Protocol ADO Protocol +337.07%
#2 GoPlus Security GoPlus Security +52.45%
#3 Starpower Starpower +36.27%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.77%
#5 GAIB AID GAIB AID +24.67%
#6 The Black Bull The Black Bull +20.07%
#7 Nockchain Nockchain +18.00%
#8 Fake World Assets Fake World Assets +17.14%
#9 DMT-NAT DMT-NAT +14.82%
#10 Casper Network Casper Network +11.97%
Coin of the day
ADO Protocol ADO Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXR
Classifica tra le azioni #33050
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm... Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Prezzo delle azioni
$0.5625
Capitalizzazione di mercato
$6.29M
Variazione (1 giorno)
-25.56%
Variazione (1 anno)
-57.71%
Paese
US
Scambia Citius Pharmaceuticals, Inc. (CTXR)

Categoria

Healthcare
Utile per Citius Pharmaceuticals, Inc. (CTXR)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Citius Pharmaceuticals, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Citius Pharmaceuticals, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE